111in-j591
mAbexperimentalImaging agent
Clinical trial activity
11 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2000 (NCT00006380)
Timeline
Indications
Studied for
Mechanism of action
- Glutamate carboxypeptidase IIBINDING AGENT
FOLH1 binding agent
- Glutamate carboxypeptidase IIRadiodepletion
FOLH1 radiodepletion
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Imaging
- 111-indium
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109678 ↗
- ChEMBLCHEMBL2109677 ↗
- ChEMBLCHEMBL2109559 ↗
- ChEMBLCHEMBL2109558 ↗
- ChEMBLCHEMBL2109549 ↗
Also known as
- 111in-j591
- 117lu-j591
- 177 lu-j591
- 177lu -j591
- 177lu-j591
- huj591
- huj591
- huj591 (111in)
- huj591 (177lu)
- huj591-gs
- j591
- j591
- j591 177lu
- muj591
- mu-j591
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06549465 | Phase 2 | Aug 6, 2024 | Convergent Therapeutics, Inc. |
| NCT02693860 | Phase 1 | Jan 1, 2016 | Cornell University |
| NCT02552394 | Phase 1 | Jul 1, 2015 | Cornell University |
| NCT00967577 | N/A | Jul 1, 2009 | Cornell University |
| NCT00859781 | Phase 2 | Jun 1, 2009 | Cornell University |
| NCT00916123 | Phase 1 | May 1, 2009 | Cornell University |
| NCT00538668 | Phase 1 | Aug 1, 2007 | Cornell University |
| NCT00195039 | Phase 2 | Aug 1, 2004 | Cornell University |
| NCT00040586 | Phase 2 | Jul 1, 2002 | BZL Biologics |
| NCT00024232 | Phase 2 | Jun 1, 2001 | Cornell University, National Cancer Institute (NCI) |
| NCT00006380 | Phase 1 | Sep 1, 2000 | Cornell University, National Cancer Institute (NCI) |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cornell University | Academic/Hospital | 9 | 9 | 3 | 2000 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 2000 |
| BZL Biologics | For profit | 1 | 1 | 1 | 2002 |
| Convergent Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2024 |
4 organizations
Page 1 / 1